Outcomes of HER2-positive non-metastatic breast cancer patients treated with anti-HER2 therapy without chemotherapy

被引:0
作者
Susanna Nguy
S. Peter Wu
Cheongeun Oh
Naamit K. Gerber
机构
[1] NYU Langone Health,Department of Radiation Oncology
[2] Holy Name Medical Center,Division of Biostastistics
[3] NYU Langone Health,undefined
来源
Breast Cancer Research and Treatment | 2021年 / 187卷
关键词
Non-metastatic breast cancer; HER2; ER; Endocrine therapy; Trastuzumab; Chemotherapy; Adjuvant treatment;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:815 / 830
页数:15
相关论文
共 362 条
[1]  
Slamon DJ(1989)Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 707-712
[2]  
Godolphin W(1994)Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells Oncogene 9 1829-1838
[3]  
Jones LA(1998)Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs Oncogene 17 2235-2249
[4]  
Holt JA(1999)Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 2639-2648
[5]  
Wong SG(1998)Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment J Clin Oncol 16 2659-2671
[6]  
Keith DE(2001)Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783-792
[7]  
Levin WJ(2001)First-line Herceptin monotherapy in metastatic breast cancer Oncology 61 37-42
[8]  
Stuart SG(2014)Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831 J Clin Oncol 32 3744-3752
[9]  
Udove J(2015)Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer N Engl J Med 372 134-141
[10]  
Ullrich A(2019)Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer J Clin Oncol 37 1868-1875